[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-399892-105":59,"doc-detail-399892-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tay-sachs-disease-lessons-from-ethnic-specific-carrier-screening-carrier-frequencies-and-inherited-disease-data","Tay-Sachs Disease: Lessons from Ethnic-Specific Carrier Screening - Carrier Frequencies and Inherited Disease Data","","Carrier screening lessons for ethnic-specific inherited disorders, centered on Tay-Sachs disease. Presents carrier frequency and at-risk couple frequency by population, alongside newborn incidence estimates for multiple conditions such as sickle cell, Gaucher, cystic fibrosis, and thalassemias. Summarizes inherited disease incidence within Ashkenazi Jews, compares selected disorders across Jewish ethnic groups (Ashkenazi, Sephardi, Oriental, Yemeni, Iraqi/Kurdish, Iranian), and outlines key clinical features of Tay-Sachs including onset, progression, autosomal recessive inheritance, high Jewish predilection, and lack of treatment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tay-sachs-disease-lessons-from-ethnic-specific-carrier-screening-carrier-frequencies-and-inherited-disease-data/399892/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tay-sachs-disease-lessons-from-ethnic-specific-carrier-screening-carrier-frequencies-and-inherited-disease-data/399892.png","ImageObject",300,407,{"name":92,"@type":93},"dhado","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-27",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which populations and diseases are included in the carrier screening data?","Question",{"text":112,"@type":113},"The document lists carrier frequencies and at-risk couple frequencies for conditions across several populations, including African-Americans (sickle cell), Ashkenazi Jews (Gaucher and Tay-Sachs), Northern Europeans (cystic fibrosis), and Greeks/Italians or Chinese/SE Asians (alpha-thalassemia variants).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is Tay-Sachs disease described in terms of symptoms and inheritance?",{"text":117,"@type":113},"Tay-Sachs is described as a fatal degenerative central nervous system disease with symptom onset around 4–8 months, progressive mental and motor degeneration, and progressive muscular weakness leading to paralysis. It is stated to follow autosomal recessive inheritance and shows strong Jewish predilection (95+%).",{"name":119,"@type":110,"acceptedAnswer":120},"What mutations are reported to cause Tay-Sachs in the Ashkenazi Jewish population?",{"text":121,"@type":113},"The document lists mutation frequencies for 1278insTATC (about 82%), IVS12 +1 (about 15%), and G269S (about 2%), along with cited sources for each mutation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},399892,1790924498,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},5909893218464,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","MOUNT SINAI CENTER FOR JEWISH GENETIC DISEASES  \nDepartment of Genetics & Genomic Sciences  \nMount Sinai School of Medicine of New York University  \nTAY-SACHS DISEASE: LESSONS FROM ETHNIC-SPECIFIC  \nCARRIER SCREENING  \nR. J. Desnick , Ph.D., M.D.  \nProfessor and Chairman Department of Genetics & Genomic Sciences Director, Mount Sinai Center for Jewish Genetics Diseases Mount Sinai School of Medicine of New York University  \nDISEASES SCREENED IN CERTAIN POPULATIONS  \n\n| Disease | Ethnic Group | Carrier Freq. | At-Risk Couple Freq. | Disease Incidence Newborns |\n| --- | --- | --- | --- | --- |\n| Sickle cell | African-Americans | 1/12 | 1/145 | 1/575 |\n| Gaucher | Ashkenazi Jews | 1/15 | 1/225 | 1/900 |\n| Tay-Sachs | Ashkenazi Jews | 1/30 | 1/900 | 1/3600 |\n| Cystic Fibrosis | Northern Europeans | 1/24 | 1/576 | 1/2300 |\n| 􀀂-Thalassemia | Greeks, Italians | 1/30 | 1/900 | 1/3600 |\n| 􀀃-Thalassemia | Chinese, SE Asians | 1/25 | 1/625 | 1/2500 |\n\nINHERITED DISEASES IN ASHKENAZI JEWS  \nDisease  \nPercent Jewish  \nEstimated Incidence  \nJewish General  \n\n| Tay-Sachs | 95 | 1 : 3600 | 1 : 300,000 |\n| --- | --- | --- | --- |\n| Gaucher Type 1 | 80 | 1 : 900 | very rare |\n| Canavan | 90 | 1 13,000 | very rare |\n| Niemann-Pick Types A & B | 80 | 1 : 30,000 | 1 : 100,000 |\n| Familial Dysautonomia | 99 | 1 : 3600 | very rare |\n| Essential Pentosuria | 99 | 1 : 2500 | very rare |\n| Factor XI Deficiency | 90 | 1 : 200 | 1 : 500 |\n| Maple Syrup Urine Disease | ? | 1 : 27,600 | 1 : 290,000 |\n| Fanconi Anemia Group C | 95 | 1 : 32,000 | rare |\n| Torsion Dystonia | 80 | 1 : 40,000 | ? |\n| Bloom Syndrome | 60 | 1 : 46,000 | very rare |\n| Mucolipidosis IV | >80 | 1 : 62,500 | ? |\n| Glycogen Storage 1a | ? | 1 : 67,500 | 1 : 100,000 |\n\nINHERITED DISEASES IN JEWISH ETHNIC GROUPS  \n\n| Ashkenazi\u003Cbr>Disease |  | Sephardi  Oriental \u003Cbr>Yemeni Iraqi/Kurdish Iranian |  |\n| --- | --- | --- | --- |\n|  |  | Gene Frequency |  |\n| Tay-Sachs Disease | .033 | rare | - - - |\n| Gaucher Disease | .067 | rare | - - - |\n| Pentosuria | .020 | - | - - - |\n| Familial Dysautonomia | .030 | - | - - - |\n| Familial Mediterranean Fever | rare | .04-.02 | - .01 - |\n| Phenylketonuria | - | rare | .015 rare \u003C .01 |\n| 􀀃-Thalassemia | - | - | .14-.04 .08-.01 - |\n| 􀀂-Thalassemia | rare | rare | rare .08-.01 .01 |\n| Dubin-Johnson Syndrome | rare | rare | - rare .03 |\n\nTAY-SACHS DISEASE  \nA Fatal Degenerative Disease of the Central Nervous System  \n• Onset of Symptoms ~ 4-8 Months:  \n– Progressive Mental and Motor Degeneration  \n– “Cherry-Red” Macular Degeneration: Blindness; Hyperacusis  \n– Progressive Muscular Weakness 􀀄 Paralysis  \n– Uncontrollable Seizures  \n• Autosomal Recessive Inheritance  \n• Jewish Predilection (95+%)  \n• Death ~ 2-5 Years of Life  \n• No Treatment Available  \nMETABOLIC DEFECT IN TAY-SACHS DISEASE  \n Okada and O’Brien. Science 165:698-700, 1968   \nGM2 GANGLIOSIDE  \nCeramide  \n􀀂-Hexosaminidase A   \nCeramide  \nGM3 GANGLIOSIDE  \nSERUM 􀀂-HEXOSAMINIDASE A ACTIVITY  \nO’Brien et al. N Engl J Med 283:15-20, 1970  \n% of Total Hexosamin idase  \n70  \n50  \n30  \n10  \n|  |  |  |  |\n| --- | --- | --- | --- |\n| | Normals |  |  |\n|  |  | Parents\u003Cbr>Patients | Relatives |\n\nMUTATIONS CAUSING TAY-SACHS DISEASE IN THE ASHKENAZI JEWISH POPULATION  \nMutation Frequency  \n1278insTATC ~82% ~~ ~~  \nIVS12 +1 ~15%  \nG269S ~ 2%    \n~99%  \n1278insTATC: Myerowitz & Costigan, JBC 263:18587, 1988 IVS12 +1 : Myerowitz, PNAS 85:3955, 1988  \nG269S: Paw et al. , PNAS 86:2413, 1989","cbCaihTVE9rZfMia","https://ap.wps.com/l/cbCaihTVE9rZfMia","pdf",425797,34,"English","# Diseases Screened in Certain Populations\n# Inherited Diseases in Ashkenazi Jews\n# Inherited Diseases in Jewish Ethnic Groups\n# Tay-Sachs Disease\n## Metabolic Defect in Tay-Sachs Disease\n## Mutations Causing Tay-Sachs Disease in the Ashkenazi Jewish Population","[{\"question\":\"Which populations and diseases are included in the carrier screening data?\",\"answer\":\"The document lists carrier frequencies and at-risk couple frequencies for conditions across several populations, including African-Americans (sickle cell), Ashkenazi Jews (Gaucher and Tay-Sachs), Northern Europeans (cystic fibrosis), and Greeks/Italians or Chinese/SE Asians (alpha-thalassemia variants).\"},{\"question\":\"How is Tay-Sachs disease described in terms of symptoms and inheritance?\",\"answer\":\"Tay-Sachs is described as a fatal degenerative central nervous system disease with symptom onset around 4–8 months, progressive mental and motor degeneration, and progressive muscular weakness leading to paralysis. It is stated to follow autosomal recessive inheritance and shows strong Jewish predilection (95+%).\"},{\"question\":\"What mutations are reported to cause Tay-Sachs in the Ashkenazi Jewish population?\",\"answer\":\"The document lists mutation frequencies for 1278insTATC (about 82%), IVS12 +1 (about 15%), and G269S (about 2%), along with cited sources for each mutation.\"}]","Tay-Sachs Disease: Lessons from Ethnic-Specific Carrier Screening - Carrier Frequencies and Inherited Disease Data | PDF",1790504857,86]